From RTTNews:

Regeneron Pharmaceuticals, Inc. reported a 3 percent decline in net income for the fourth quarter to $1.16 billion or $10.19 per share. Adjusted earnings were $1.37 billion or $11.86 per share. Total revenue for the quarter edged up 1 percent to $3.43 billion, with a 14 percent growth excluding Ronapreve. Analysts expected earnings of $10.87 per share and revenues of $3.29 billion. (RTT News)



Read more: Regeneron Pharma Q4 Results Top Estimates